Table 1 Baseline characteristics of the UPLIFT® study population
Tiotropium (n = 2986) | Control (n = 3006) | Total (N = 5992) | |
|---|---|---|---|
Male, % | 75 | 74 | 75 |
Mean (SD) age, y | 65 (8) | 65 (8) | 65 (8) |
Current smoker, % | 29 | 30 | 30 |
Mean (SD) duration of COPD, y | 10 (8) | 10 (7) | 10 (7) |
GOLD stage, % | |||
II | 46 | 45 | 46 |
III | 44 | 44 | 44 |
IV | 8 | 9 | 9 |
Mean (SD) prebronchodilator | |||
FEV1, L | 1.1 (0.4) | 1.1 (0.4) | 1.1 (0.4) |
FEV1, % predicted value | 40 (12) | 39 (12) | 39 (12) |
FVC, L | 2.6 (0.8) | 2.6 (0.8) | 2.6 (0.8) |
FEV1/FVC ratio, % | 42 (11) | 42 (11) | 42 (11) |
Mean (SD) postbronchodilator | |||
FEV1, L | 1.3 (0.4) | 1.3 (0.4) | 1.3 (0.4) |
FEV1, % predicted value | 48 (13) | 47 (13) | 48 (13) |
FVC, L | 3.1 (0.9) | 3.1 (0.9) | 3.1 (0.9) |
FEV1/FVC ratio, % | 44 (11) | 43 (11) | 43 (11) |
Mean (SD) SGRQ total score, units | 46 (17) | 46 (17) | 46 (17) |
Patients with comorbidities, n (%) | |||
Vascular disorders | 1353 (45.3) | 1367 (45.5) | 2720 (45.4) |
Cardiac disorders | 790 (26.5) | 765 (25.5) | 1555 (26.0) |
Respiratory, thoracic and mediastinal disorders | 565 (18.9) | 593 (19.7) | 1158 (19.3) |